Transmyocardial Revascularization (TMR)

Modified on 2009/10/14 21:41 by admin
The U.S. Food and Drug Administration (FDA) approved transmyocardial revascularization (TMR) in 1998 for the treatment of severe chest pains. The TMR system uses a laser to create tiny holes in the myocardium in areas inaccessible to treatment by coronary artery bypass or angioplasty. According to the manufacturers, CardioGeneis and PLC Medical Systems, myocardium holes help relieve pain by allowing more blood to reach the heart.

The FDA recently commissioned a study on the risks of TMR after receiving reports that surgeons were using the laser treatment on patients who did not qualify for the procedure. Researchers involved in the study found that TMR is often performed while patients are having bypasses, an unapproved use. Out of the 3,136 patients who underwent TMR from 1998 to 2001, only 21 percent met the FDA's criteria for treatment.

The study, published in the November 2003 issue of The Journal of the American College of Cardiology, also discovered serious risks associated with TMR. One in 16 who underwent TMR died while one in six suffered serious injuries, including kidney failure and strokes. Patients who had suffered a heart attack in the three weeks before undergoing TMR and those who had angina were twice as likely to die than patients without the disorders.

If you have been seriously injured during a surgical procedure, it may be important to contact an attorney who can help you protect your legal rights. Please keep in mind that there may be time limits within which you must commence suit.

See Also

  1. Medical Procedures: Overview
  2. Kidney Failure
  3. Stroke
  Name Size